To assess the efficacy of progesterone and progestogens in the treatment of premenstrual syndrome.
How were the studies combined? Studies of progesterone therapy and progestogen therapy were analysed separately. An overall standardised mean difference (SMD) and 95% confidence interval (CI) for the proportion of women who improved was calculated using a random-effects model, then converted to an odds ratio (OR). Publication bias was assessed using regression analysis.
How were differences between studies investigated? Statistical homogeneity was assessed using the chi-squared test, taking a P-value of less than 0.05 to indicate significant heterogeneity. Results for progesterone were analysed separately according to the mode of administration (suppositories or pessaries, and oral).
Results of the review
Ten RCTs (531 women) of progesterone therapy and four RCTs (378 women) of progestogen therapy were included.
Progesterone.
Placebo was marginally more effective at reducing symptoms than progesterone suppositories or pessaries. The SMD (8 RCTs) was 0.04 (95% CI: 0.03, 0.05) and the OR was 0.93 (95% CI: 0.91, 0.95). Micronised progesterone significantly reduced symptoms compared with placebo. The SMD (3 RCTs) was -0.15 (95% CI: -0.17, -0.12) and the OR was 1.30 (95% CI: 1.25, 1.36). For all routes of administration combined, there was no clinically significant difference between progesterone and placebo, though progesterone was statistically significantly better than placebo. The SMD was -0.028 (95% CI: -0.040, -0.017) and the OR was 1.05 (95% CI: 1.03, 1.08). No significant heterogeneity was found (P=0.999).
Progestogen.
Progestogen significantly reduced symptoms compared with placebo. The SMD was -0.036 (95% CI: -0.059, -0.014) and the OR was 1.07 (95% CI: 1.03, 1.11). No significant heterogeneity was found (P=0.999).
There was no evidence of publication bias.
Side effects.
The most common side-effects reported for progesterone were an alteration in the length of menstrual cycle with progesterone suppository or pessary, and fatigue or sedation with oral micronised progesterone. There was no significant difference between progesterone and placebo or between progestogens and placebo in the proportion of withdrawals due to side-effects. The ORs were 1.66 (95% CI: 0.43, 6.79) and 1.65 (95% CI: 0.86, 3.21) in the progesterone and progestogen groups, respectively.
Authors' conclusions
There was no evidence from the review that progesterone or progestogens are more effective than placebo in treating premenstrual syndrome.
CRD commentary
The review question was clear in terms of the study design, intervention and participants. The participants were required to have a pre-trial diagnosis of premenstrual syndrome, but no criteria were stated as a requirement for this diagnosis. Several relevant databases were searched, the search terms were stated and no language limitations were applied. Two reviewers extracted the data and this reduced the potential for bias and errors. However, the methods used to select the studies were not described. Validity was assessed using defined criteria and some relevant information on the included studies was tabulated. It was not clear which of the many outcomes assessed in the individual studies were used to calculate the main outcome (proportion with improved symptoms) in the review. The studies were appropriately grouped by type of therapy and combined in a meta-analysis, and statistical heterogeneity was tested. The authors commented on the clinical significance of the results, but it was unclear whether this level had been determined a priori. The evidence presented tends to support the authors' conclusions.
